The Technical Analyst
Anixa Biosciences Inc [ANIX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Anixa Biosciences Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
3.58% $3.18
America/New_York / 24 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 101.44 mill |
| EPS: | -0.340 |
| P/E: | -9.35 |
| Earnings Date: | Mar 12, 2024 |
| SharesOutstanding: | 31.90 mill |
| Avg Daily Volume: | 0.116 mill |
| RATING 2024-04-24 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | n/a | n/a | n/a | |||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -9.35 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.59x |
| Company: PE -9.35 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.0083 (-99.74%) $-3.17 |
| Date: 2024-04-25 |
| Expected Trading Range (DAY) |
|---|
|
$ 2.91 - 3.45 ( +/- 8.62%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-09 | Titterton Lewis H Jr | Buy | 15 009 | Common Stock |
| 2024-03-15 | Baskies Arnold M | Buy | 10 000 | Common Stock |
| 2024-03-15 | Kumar Amit | Buy | 30 000 | Common Stock |
| 2024-01-12 | Baskies Arnold M | Buy | 25 000 | Employee Stock Option (Right to Buy) |
| 2024-01-12 | Gottschalk Emily | Buy | 25 000 | Employee Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 60.81 |
| Last 100 transactions |
| Buy: 11 656 359 | Sell: 3 491 117 |
Forecast:
16:00 - $3.20
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $3.20
Forecast 2: 16:00 - $3.20
Forecast 3: 16:00 - $3.20
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $3.18 (3.58% ) |
| Volume | 0.356 mill |
| Avg. Vol. | 0.116 mill |
| % of Avg. Vol | 307.98 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ANIX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ANIX
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Last 10 Buy Signals
Latest Press Releases
2024-04-18 08:20:00 - Press Release
Anixa Biosciences Welcomes Celebrity Oncologist Dr. Sanjay Juneja To Its Cancer Business Advisory Board
San jose, calif., april 18, 2024 /prnewswire/ -- anixa biosciences, inc. ("anixa" or the "company") (nasdaq: anix), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced the appointment of sanjay juneja, md to its cancer business advisory board.
2024-03-14 08:45:00 - Press Release
Anixa Biosciences 2024 Annual Meeting Of Stockholders To Include Investor Presentation Open To All Interested Parties
San jose, calif., march 14, 2024 /prnewswire/ -- anixa biosciences, inc. ("anixa" or the "company") (nasdaq: anix), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced that it will host its 2024 annual meeting of stockholders (the "meeting") on thursday, march 21, 2024 at 10:00 a.m.
2024-03-11 08:00:00 - Press Release
Anixa Biosciences Announces Presentation At 24th Annual World Vaccine Congress
San jose, calif., march 11, 2024 /prnewswire/ -- anixa biosciences, inc. ("anixa" or the "company") (nasdaq: anix), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced that dr. amit kumar, chairman and ceo of anixa, will participate in the 24th annual world vaccine congress being held april 1-4, 2024.
2024-02-12 07:30:00 - Press Release
Anixa Biosciences Initiates Dosing In Second Cohort Of Ovarian Cancer Car-t Clinical Trial
Dose escalation for fourth patient follows successful completion of first cohort san jose, calif. , feb. 12, 2024 /prnewswire/ -- anixa biosciences, inc. ("anixa" or the "company") (nasdaq: anix), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced that treatment has commenced for the fourth patient in the ongoing phase 1 clinical trial of its novel chimeric antigen receptor t-cell (car-t) therapy for ovarian cancer.
2024-01-29 08:50:00 - Press Release
Anixa Biosciences Announces Participation In 2024 Neauxcancer Oncology Conference
Conference investment track spotlights promising and emerging biotech and healthcare companies advancing the field of oncology san jose, calif. , jan. 29, 2024 /prnewswire/ -- anixa biosciences, inc. ("anixa" or the "company") (nasdaq: anix), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced its participation in the 2024 neauxcancer conference organized by the cancer advocacy group of louisiana (cagla), being held february 29 – march 2, 2024 in new orleans.
Latest News
2023-12-14 07:15:00 - PRNewsWire
Anixa Biosciences to Present at Biotech Showcase 2024
SAN JOSE, Calif. , Dec. 14, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced that it will present an overview of its business and provide updates on its clinical programs at Biotech Showcase, taking place January 8-10, 2024 in San Francisco, California in parallel to the 42nd Annual J.P.
2023-12-11 12:26:14 - InvestorPlace
3 Biotech Stocks to Turn $5,000 Into $1 Million: December 2023
Some of the most explosive opportunities can be found in biotech stocks. Look at CRISPR Therapeutics (NASDAQ: CRSP ), for example.
2023-12-06 16:05:00 - PRNewsWire
Anixa Biosciences to Host Conference Call This Evening to Discuss Positive New Data from Ongoing Phase 1 Study of Breast Cancer Vaccine
– Data to be released at approximately 6:00 p.m. ET, following presentation at 2023 SABCS – – Conference call to commence at 6:30 p.m.
2023-11-09 11:02:04 - Zacks Investment Research
FATE Q3 Earnings Beat on Lower Expenses, Revenues Fall Y/Y
FATE reports better-than-expected third-quarter 2023 financial results, driven by lower operating expenses. The stock rises about 5% in the after-market hours.
2023-09-21 13:32:40 - Zacks Investment Research
ANIXA BIOSCIENCES INC (ANIX) Upgraded to Buy: What Does It Mean for the Stock?
ANIXA BIOSCIENCES INC (ANIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2023-09-11 22:11:25 - InvestorPlace
The 3 Most Undervalued Cheap Stocks to Buy in September 2023
The United States Treasury Secretary, Janet Yellen, recently expressed her confidence in the economy's ability to recover from the recession without causing significant harm to the job market or sparking excessive inflation. She believes that the United States will successfully navigate this economic challenge, maintaining control over consumer-price increases.This is leading to many investors considering cheap stocks to buy.
2023-06-22 13:21:23 - Zacks Investment Research
What Makes ANIXA BIOSCIENCES INC (ANIX) a New Buy Stock
ANIXA BIOSCIENCES INC (ANIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2023-04-25 11:32:42 - Zacks Investment Research
Is Anixa Biosciences (ANIX) Outperforming Other Medical Stocks This Year?
Here is how ANIXA BIOSCIENCES INC (ANIX) and Intuitive Surgical, Inc. (ISRG) have performed compared to their sector so far this year.
2023-04-18 19:13:41 - Seeking Alpha
Anixa: I Am More Bullish After Efficacy Data For Its Triple-Negative Breast Cancer Vaccine
Anixa: I Am More Bullish After Efficacy Data For Its Triple-Negative Breast Cancer Vaccine
2023-04-18 12:55:10 - Zacks Investment Research
Anixa (ANIX) Falls 25% Despite Positive Breast Cancer Study Data
Anixa Biosciences (ANIX) announces positive top-line data from its phase Ia study evaluating the safety of its breast cancer vaccine. However, the stock plunges 25% in the absence of efficacy reports.